Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27895748 | 0.91 | TACR1 (0.53) | TACR1MMP9ALDH1A1MEN1HPGD | |
| SCHEMBL13788325 | 0.90 | ALDH1A1 (0.60) | TACR1MMP9ALDH1A1ALOX15CASP1 | |
| SCHEMBL15996601 | 0.89 | ALDH1A1 (0.55) | MMP9ALDH1A1MAPK1L3MBTL1ALOX15 | |
| SCHEMBL890103 | 0.89 | ALDH1A1 (0.55) | MMP9ALDH1A1MAPK1L3MBTL1ALOX15 | |
| SCHEMBL25491992 | 0.84 | TACR1 (0.59) | TACR1MMP9ALDH1A1MEN1HPGD | |
| SCHEMBL25491998 | 0.84 | TACR1 (0.59) | TACR1MMP9ALDH1A1MEN1HPGD | |
| SCHEMBL3540630 | 0.84 | RAB9A (0.54) | TACR1MMP9ALDH1A1MEN1HPGD | |
| SCHEMBL3537933 | 0.84 | GPR132 (0.51) | TACR1MMP9ALDH1A1 | |
| SCHEMBL16668017 | 0.82 | ALDH1A1 (0.57) | TACR1MMP9ALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL6940522 | 0.81 | SLC15A1 (0.53) | TACR1MMP9ALDH1A1MEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022722-B2 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20060047000-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS, INC. (US) | 2006-03-02 | — | — | US | disclosed |
| US-6958355-B2 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-20050075379-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2005-04-07 | — | — | US | disclosed |
| US-20050037997-A9 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2005-02-17 | — | — | US | disclosed |
| US-6768008-B2 | FOR THERAPY | ARYX THERAPEUTICS | 2004-07-27 | — | — | US | disclosed |
| EP-1430039-A2 | ARYL DERIVATIVES FOR THE TREATMENT OF DIABETES, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | Aryx Therapeutics (US) | 2004-06-23 | — | — | EP | disclosed |
| US-6680387-B2 | USING THIAZOLIDINONE COMPOUND | ARYX THERAPEUTICS | 2004-01-20 | — | — | US | disclosed |
| US-20030236227-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | ARYX THERAPEUTICS | 2003-12-25 | — | — | US | disclosed |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-04-03 | — | — | US | disclosed |
| EP-1276730-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYx Therapeutics (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001081328-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYX THERAPEUTICS (US) | 2001-11-01 | — | — | WO | disclosed |
| US-6160124-A | Method for treating or preventing arteriosclerosis | JAPAN TOBACCO INC. (JP) | 2000-12-12 | — | — | US | disclosed |
| US-6057343-A | HAVE SUPERIOR HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIONS AND ARE USEFUL FOR THE TREATMENT OF DIABETES AND THE COMPLICATIONS THEREOF, AS WELL AS THERAPEUTIC AGENTS FOR RELATED DISEASES SUCH AS HYPERLIPIDEMIA | JAPAN TOBACCO, INC. (JP) | 2000-05-02 | — | — | US | disclosed |
| US-6037359-A | ARTERIOSCLEROSIS PREVENTION; ANTIDIABETIC AGENTS; ANTILIPEMIC AND HYPOGLYCEMIC AGENTS | JAPAN TOBACCO, INC. (JP) | 2000-03-14 | — | — | US | disclosed |
| US-5939445-A | ISOXAZOLIDINEDIONES COMPOUNDS AS HYPOGLYCEMIC AGENTS AND TREATMENT OF ARTERIOSCLEROSIS | JAPAN TOBACCO, INC. (JP) | 1999-08-17 | — | — | US | disclosed |
| EP-0684242-B1 | ISOXAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | JAPAN TOBACCO INC (JP) | 1999-05-06 | — | — | EP | disclosed |
| US-5728720-A | HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; TREATMENT OF DIABETES | JAPAN TOBACCO INC. (JP) | 1998-03-17 | — | — | US | disclosed |
| EP-0684242-A1 | ISOXAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | JAPAN TOBACCO INC. (JP) | 1995-11-29 | — | — | EP | disclosed |
| EP-0603419-A1 | NOVEL THIAZOLIDINEDIONE COMPOUND AND USE THEREOF | Japan Tobacco Inc. (JP) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236227-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TACR1 1039/4885MMP9 1014/4885ALDH1A1 525/4885 |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TACR1 1039/4885MMP9 1014/4885ALDH1A1 525/4885 |
| US-20060047000-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TACR1 1039/4885MMP9 1014/4885ALDH1A1 525/4885 |
| US-20050037997-A9 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TACR1 1039/4885MMP9 1014/4885ALDH1A1 525/4885 |
| US-20050075379-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | TACR1 1039/4885MMP9 1014/4885ALDH1A1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.